- The smoking gun nobody's talking about
- Why Lilly had every reason to make it work
- The 4,813-dalton problem
- What Lilly did instead: a completely different molecule
- So what are compounded oral tirzepatide pharmacies actually selling?
- The Day v. OpenLoop lawsuit
- If you want an oral GLP-1, here's what actually works
- FAQ
The smoking gun nobody's talking about
Compounded oral tirzepatide is a real category in 2026. Telehealth companies sell it as tablets, ODTs, sublingual drops, and troches. Prices range from $249 to $500 per month. Marketing suggests it delivers the same weight-loss benefits as injectable Mounjaro or Zepbound, in a more convenient form.
Here is the problem with all of that.
The company that invented tirzepatide, holds the patents, owns the FDA-approved injectable products (Mounjaro for diabetes, Zepbound for obesity), and collected more than $14 billion in tirzepatide revenue in 2025 — Eli Lilly — had every commercial incentive imaginable to develop an oral version.
They did not.
Instead, when Lilly wanted a daily oral GLP-1 medication to compete with Novo Nordisk's Rybelsus and oral Wegovy, they spent roughly a decade developing a completely different molecule called orforglipron — now marketed as Foundayo, approved by the FDA on April 1, 2026.
The question every patient considering compounded oral tirzepatide should ask is: if the company with the patents, the billion-dollar lab, the unlimited regulatory pathway, and the direct financial motive to make oral tirzepatide work chose not to — what is a compounding pharmacy doing that Lilly couldn't?
Eli Lilly's decision to develop orforglipron instead of oral tirzepatide is the single most damning piece of evidence about compounded oral tirzepatide's scientific basis. It is also almost never discussed in the marketing that sells these products.
Why Lilly had every reason to make it work
To understand how significant Lilly's decision is, walk through what they actually had on their side:
1. The patent position
Lilly holds the foundational patents on tirzepatide. Any oral tirzepatide product would have been a Lilly product, protected from generic competition for many years. A successful oral tirzepatide would have been one of the most profitable drugs in pharmaceutical history.
2. The market opportunity
Oral GLP-1 for weight loss is, by analyst consensus, a $10–$20 billion annual market by 2030. Lilly was competing with Novo Nordisk, which already had Rybelsus on the market and the Wegovy pill in development. An oral tirzepatide would have let Lilly offer both injectable and oral formats, matching Novo's portfolio position.
3. The R&D resources
Lilly's pharmaceutical R&D budget in 2024 was approximately $9.2 billion. The company has some of the world's leading peptide chemistry, formulation, and pharmacokinetics teams. If anyone had the scientific resources to make oral tirzepatide viable, it was Lilly.
4. The regulatory pathway
Lilly could have pursued FDA approval for oral tirzepatide through the standard 505(b)(1) new drug application pathway, the same way Novo Nordisk did for Rybelsus. The regulatory template existed. The precedent was established.
5. The formulation technology access
Through licensing, partnership, or in-house development, Lilly could have pursued any of the absorption-enhancement approaches that exist for oral peptides — including SNAC-style enhancers, permeation enhancers, enteric coatings, and nanoparticle delivery systems. Nothing was scientifically off-limits to them.
And yet, Lilly's publicly disclosed oral GLP-1 strategy went in an entirely different direction.
The 4,813-dalton problem
Tirzepatide is a peptide with a molecular weight of 4,813 daltons. It is a 39-amino-acid chain, slightly longer and heavier than semaglutide (4,113 daltons). And the extra 700 daltons matters.
The intestinal barrier is not a sharp cutoff — it is a steep gradient. Every additional unit of molecular weight makes passive absorption exponentially harder. At 4,813 daltons, tirzepatide is near the upper edge of what any absorption-enhancement technology can plausibly push across the gut wall in meaningful quantities.
Consider the comparison:
| Molecule | Molecular weight | Oral bioavailability | Notes |
|---|---|---|---|
| Ibuprofen | 206 daltons | ~80–100% | Small molecule, easy absorption |
| Insulin | 5,808 daltons | <0.1% | No successful oral insulin product |
| Semaglutide (Rybelsus) | 4,113 daltons | ~0.4–1% | Required decade of SNAC formulation R&D |
| Tirzepatide | 4,813 daltons | No published human oral PK data | Lilly chose not to pursue oral version |
Oral semaglutide, with its 700-fewer daltons and Novo Nordisk's specific SNAC workaround, achieves roughly 0.4–1% bioavailability under ideal conditions. Tirzepatide is 17% larger by mass. The absorption math gets worse, not better, as molecules get bigger.
There is no published, peer-reviewed human pharmacokinetic data for orally-administered tirzepatide demonstrating meaningful systemic absorption of the intact peptide. Not from Lilly. Not from compounding pharmacies. Not from independent researchers. The data simply does not exist in the published literature as of this writing.
Absence of evidence is not proof of zero absorption. It is possible — in a technical, theoretical sense — that some small fraction of oral tirzepatide reaches systemic circulation in some patients under some conditions. What the absence of published data does mean is that no one has demonstrated this effect reliably enough to publish it, and that any claims about oral tirzepatide effectiveness rely on patient anecdote rather than pharmacokinetic evidence.
What Lilly did instead: a completely different molecule
Orforglipron (brand name Foundayo) is not oral tirzepatide. It is not oral semaglutide. It is not a peptide at all.
It is a small-molecule GLP-1 receptor agonist — meaning it binds the same receptor that GLP-1 binds, but the molecule itself is a synthetic small-molecule drug, roughly 1/10 the molecular weight of semaglutide or tirzepatide. Small molecules pass through the gut wall easily. They do not need absorption enhancers. They do not require a fasting protocol.
Orforglipron was originally discovered at Chugai Pharmaceutical in Japan. Lilly licensed it in 2018 and developed it through Phase 3 trials (the ATTAIN program) leading to the April 2026 FDA approval.
The pattern here is not subtle. Lilly spent the better part of a decade developing a non-peptide oral GLP-1 when they could have spent that same decade trying to crack oral tirzepatide. They chose the harder, slower path of discovering a new molecule. This is not what a company does when a simpler solution is available.
Weight loss at the highest Foundayo dose in the ATTAIN-1 trial was approximately 11.2% at 72 weeks — less than the roughly 21% that injectable tirzepatide produces, but in the range achievable for an oral compound. That gap — roughly 10 percentage points — is, in a sense, the cost of admission for orally-deliverable GLP-1 activity. Lilly accepted that cost because the alternative (trying to make oral tirzepatide work) was not viable.
If a $700-billion-market-cap pharmaceutical company with unlimited R&D resources concluded that the path to a successful oral GLP-1 product ran through inventing a new molecule rather than reformulating tirzepatide, a reasonable consumer should take that conclusion seriously.
So what are compounded oral tirzepatide pharmacies actually selling?
That is the right question, and the answer is not simple.
Compounded oral tirzepatide products on the telehealth market in 2026 fall into a few categories:
Tablets claiming gastrointestinal absorption
Some products claim standard gut absorption like any oral drug. As discussed above, there is no published evidence that meaningful systemic absorption of 4,813-dalton peptide occurs through the intestinal barrier without a specialized enhancer.
ODTs and sublingual formulations claiming oral mucosal absorption
Some products claim that tirzepatide is absorbed through the lining of the mouth, sidestepping the gut entirely. The oral mucosa does absorb some small molecules effectively (nitroglycerin, for example). Published data on peptide absorption through the oral mucosa at the scale of tirzepatide is limited and generally unfavorable — large peptides do not easily cross oral mucosal tissue in therapeutic quantities.
Products with proprietary "enhancer" blends
Some compounded products include proprietary permeation-enhancer blends that the compounding pharmacy claims improve absorption. Without published pharmacokinetic studies on the specific formulations, there is no way to verify these claims. This is not the same as proof that they do not work — it is an absence of evidence either way.
Products using tirzepatide salt forms
Some compounded products use tirzepatide as a sodium salt or other salt form that may not be pharmaceutically equivalent to the base tirzepatide in FDA-approved products. The FDA has publicly expressed concern about this practice.
Patients who purchase compounded oral tirzepatide and report weight loss are not lying — they are describing a real experience. What is less certain is the mechanism. Weight loss in people who start a structured weight-management program commonly has multiple contributing factors: dietary changes, increased attention to eating behavior, placebo response (which is robust in obesity pharmacology), and any pharmacological effect from the medication. Disentangling these is difficult without controlled trials, which compounded oral tirzepatide has not been subject to.
The Day v. OpenLoop lawsuit
Some of these questions are now being tested in federal court. Day v. OpenLoop Health (Case 1:25-cv-01418, filed in the U.S. District Court for the District of Delaware on November 20, 2025) is a class-action complaint against OpenLoop Health and Triad Rx concerning the marketing and efficacy of compounded oral tirzepatide tablets.
The complaint raises, in effect, the question this article has been circling: whether compounded oral tirzepatide has any viable pharmacokinetic pathway for systemic absorption of the intact peptide, and whether marketing that implies equivalence to injectable tirzepatide is false or misleading.
As of this writing, the case has not been decided. We are not predicting an outcome. But the case exists, it was filed by named plaintiffs with legal counsel willing to take on telehealth GLP-1 defendants, and it raises the scientific question in a forum where evidence must actually be produced.
Patients considering compounded oral tirzepatide should be aware of the pending litigation as a relevant fact in their decision.
If you want an oral GLP-1, here's what actually works
Oral GLP-1 with demonstrated bioavailability and FDA approval is a short list as of April 2026. All of these are brand-name products available by prescription:
- Rybelsus — oral semaglutide with SNAC. Approved for T2D since 2019. Requires fasting protocol. 0.4–1% bioavailability but doses are calibrated accordingly.
- Wegovy pill — oral semaglutide with SNAC, higher dose than Rybelsus. Approved for weight loss December 2025. Same fasting protocol.
- Foundayo (orforglipron) — non-peptide small molecule. FDA-approved April 2026. No fasting protocol. Starting $149/month via LillyDirect self-pay.
None of these are oral tirzepatide. Oral tirzepatide does not exist as an FDA-approved product and is not on Lilly's announced pipeline.
Sesame Care — for FDA-approved oral GLP-1s with real absorption data
If you want an oral GLP-1 with published bioavailability, established dosing, and a clear regulatory path, Sesame Care connects you with licensed clinicians who can prescribe Rybelsus, Wegovy pill, or Foundayo. Novo Nordisk Recognized Care Provider. Brand-name only.
Injectable tirzepatide is what actually works
If you want real tirzepatide with real bioavailability and real published trial data — roughly 21% weight loss at 72 weeks in SURMOUNT-1 — the answer is injectable Mounjaro or Zepbound, not an oral compounded version. SHED can connect you with telehealth clinicians for FDA-approved injectable GLP-1 prescriptions as well as compounded options. Compounded medications are not FDA-approved.
Bottom line
The strongest evidence against compounded oral tirzepatide is not a clinical trial or an FDA warning letter. It is Eli Lilly's decision to spend a decade and enormous R&D resources developing an entirely different molecule — orforglipron — rather than trying to make oral tirzepatide work. If the company with every reason and every resource to do it chose not to, consumers should take that as a meaningful signal.
This does not mean anyone taking compounded oral tirzepatide is getting nothing. It does mean that whatever you are getting is not what the marketing implies, and that your weight loss — if it happens — may have more to do with the behavioral changes that accompany starting any weight program than with the specific peptide you are swallowing.
For an oral GLP-1 that actually has the science behind it, Foundayo is the drug Lilly built as the answer to this question. Rybelsus and the Wegovy pill have the SNAC workaround and decades of semaglutide data. These are the paths with evidence.
Is compounded oral tirzepatide illegal?
Compounding itself is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act. What the FDA has challenged in its 2026 enforcement wave is how compounded oral tirzepatide and compounded oral semaglutide have been marketed — specifically, claims that imply FDA approval or equivalence to brand-name products. The medications themselves are not categorically illegal; the marketing around them has been extensively cited.
Why do some people report weight loss on compounded oral tirzepatide?
Several factors can contribute to weight loss reports beyond pharmacological effect: placebo response (which is meaningful in obesity pharmacology), dietary changes that commonly accompany starting a weight-loss program, increased mindful eating, and any clinician-directed behavioral coaching included in the program. Isolating the specific contribution of the compounded medication without a controlled trial is not possible.
Could someone eventually make oral tirzepatide work?
Possibly. Pharmaceutical science advances. But the absence of any major pharmaceutical company pursuing oral tirzepatide — not Lilly, not Novo Nordisk, not any of the roughly dozen large pharma companies with relevant capabilities — suggests the scientific community has collectively concluded the path is not promising relative to alternatives.
What about compounded oral semaglutide?
Compounded oral semaglutide faces similar but somewhat less severe issues. Semaglutide is smaller (4,113 daltons vs tirzepatide's 4,813) and there is at least a proof of concept (Novo Nordisk's SNAC formulation) demonstrating that oral semaglutide absorption is achievable. Whether a compounded formulation without SNAC achieves meaningful absorption is a separate question with limited published evidence.
If I want oral tirzepatide effects, what should I take?
The closest options in 2026 are: (1) Foundayo (orforglipron) orally, which has less weight loss than injectable tirzepatide but real oral pharmacokinetics; (2) injectable tirzepatide (Mounjaro or Zepbound), which has the full trial weight loss. There is no FDA-approved oral tirzepatide product.